|

RNDO-564 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Rondo Therapeutics1

Indications

  • Gastroesophageal Junction (GEJ) Adenocarcinoma1
  • Solid Tumors (Phase 1)1
  • Head and Neck Squamous Cell Cancer1
  • Esophageal Squamous Cell Cancer1
  • Urothelial Carcinoma Bladder1

Huntersville, North Carolina1 trial

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Carolina Biooncology

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.